See What HealthDay Can Do For You
Contact Us

AHA: Retinal Damage Linked to Atrial Fibrillation

Micro-vessel damage in the retina and kidney associated with a higher risk

AHA: Retinal Damage Linked to Atrial Fibrillation

MONDAY, Nov. 18, 2013 (HealthDay News) -- Micro-vessel damage in the eye and kidneys is associated with a higher risk of developing atrial fibrillation, according to a study presented at the American Heart Association's 2013 Scientific Sessions, held from Nov. 16 to 19 in Dallas.

Sunil K. Agarwal, M.B.B.S., M.P.H., Ph.D., from Johns Hopkins University in Baltimore, and colleagues examined the association between micro-vessel abnormalities in the retina and kidneys and atrial fibrillation in 10,009 middle-aged adults. At baseline, 7.1 percent had retinopathy (3 percent retinal hemorrhage and 4 percent retinal micro-aneurysms) and 7.2 percent had micro-albuminuria.

During an average follow-up of 13.6 years, the researchers observed that 1,100 adults developed atrial fibrillation. Per 1,000 person-years, the incidence of atrial fibrillation was 24.4 for those with both retinopathy and micro-albuminuria, 16.8 for those with micro-albuminuria only, 8.9 for those with retinopathy only, and 5.7 for neither. After adjusting for various cardiovascular risk factors, the hazard ratio was 1.37 for atrial fibrillation with retinopathy, 1.60 for atrial fibrillation with retinal hemorrhage, and 1.47 for atrial fibrillation with retinal micro-aneurysms.

"Signs of micro-vessel disease in retina and kidneys are independently and interactively associated with higher risk of atrial fibrillation," Agarwal and colleagues conclude.

Abstract
More Information

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.